<SEC-DOCUMENT>0001193125-21-225718.txt : 20210727
<SEC-HEADER>0001193125-21-225718.hdr.sgml : 20210727
<ACCEPTANCE-DATETIME>20210727163638
ACCESSION NUMBER:		0001193125-21-225718
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210727
FILED AS OF DATE:		20210727
DATE AS OF CHANGE:		20210727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		211117996

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d181764d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;27, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d181764dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g181764g0727161047435.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>the Shanghai Stock Exchange </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI,
China &#150; July&nbsp;27, 2021 &#150;</B> <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the &#147;Company&#148;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel
biologics, today announced that on July&nbsp;27, 2021, the Board of Directors of the Company (the &#147;Board&#148;) approved a preliminary proposal for the potential dual listing of the Company&#146;s newly issued shares on the Science and
Technology Innovation Board of the Shanghai Stock Exchange (the &#147;STAR Board&#148;). The Board also authorized certain officers to execute the Listing Tutoring Agreement between the Company and the Sponsor China International Capital Corporation
Limited (the &#147;Tutoring Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proposed dual listing on the STAR Board is expected to be completed in 2022, conditional upon and
subject to, among other things, market conditions, further approval of the Board and potentially of the Shareholders at a general meeting of the Company, and the obtaining of the necessary regulatory approvals. Shareholders and potential investors
should exercise caution when dealing in the securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the signing of the Tutoring Agreement, the Company will proceed to make a
filing with the Shanghai Branch of China Securities Regulatory Commission for entering the IPO tutoring program, as required by the relevant rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are making concrete progress in our plan to pursue further equity listings on Greater China stock exchanges (including Shanghai Stock Exchange and
Hong Kong Stock Exchange,&#148; said Jielun Zhu, CFO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;The potential dual listing on the STAR Board in China will enable us to tap into a complementary shareholder base in the onshore market to
support our exciting growth and transition into a fully-integrated global biopharma company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will make further announcement(s) to
disclose any material updates and progress in respect of the proposed dual listing in accordance with applicable laws and regulations as and when appropriate. This announcement is for information purposes only and does not constitute, or form part
of, any invitation or offer to acquire, purchase or subscribe for any securities of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of
immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients around the world through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> innovative pipeline of more than 10
clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s <FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies through internal R&amp;D and
global partnerships. The Company is on track to transition from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&amp;D capabilities, world-class GMP manufacturing facilities and
commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit
<U><FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT></U> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on <U>LinkedIn</U>, <U>Twitter</U> and <U>WeChat</U>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>www.i-mabbiopharma.com</U></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g181764g0727161047435.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement contains forward-looking statements. These statements are made under the &#147;safe harbor&#148; provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#147;will,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;future,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;confident&#148; and similar statements. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the &#147;SEC&#148;),
in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about
I-Mab&#146;s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any
forward-looking statement, including but not limited to the following: <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which
may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property for
its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history
and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT>
and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jielun Zhu <BR>Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT
STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT></U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng <BR>Chief Communications Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT
STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emilie Wu</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District Shanghai, China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U><FONT STYLE="white-space:nowrap">www.i-mabbiopharma.com</FONT></U></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g181764g0727161047435.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g181764g0727161047435.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y )P# 2(  A$! Q$!_\0
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M8OA*'_A'[FT>WM6O93(5F*="S$CG&>]%X"M,M:CJ,=EI-G+!I\4LTX7R[?
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@KK-A:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:2BB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
